MX2020009140A - Metodos para el tratamiento de enfermedades oculares. - Google Patents

Metodos para el tratamiento de enfermedades oculares.

Info

Publication number
MX2020009140A
MX2020009140A MX2020009140A MX2020009140A MX2020009140A MX 2020009140 A MX2020009140 A MX 2020009140A MX 2020009140 A MX2020009140 A MX 2020009140A MX 2020009140 A MX2020009140 A MX 2020009140A MX 2020009140 A MX2020009140 A MX 2020009140A
Authority
MX
Mexico
Prior art keywords
methods
ocular diseases
treating ocular
treating
diseases
Prior art date
Application number
MX2020009140A
Other languages
English (en)
Inventor
Amy Racine
Andreas Weichselberger
James Warburton
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2020009140A publication Critical patent/MX2020009140A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporciona un método para tratar a un paciente que tiene una enfermedad ocular neovascular.
MX2020009140A 2018-03-16 2019-03-08 Metodos para el tratamiento de enfermedades oculares. MX2020009140A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862643887P 2018-03-16 2018-03-16
US201962805344P 2019-02-14 2019-02-14
PCT/IB2019/051899 WO2019175727A1 (en) 2018-03-16 2019-03-08 Methods for treating ocular diseases

Publications (1)

Publication Number Publication Date
MX2020009140A true MX2020009140A (es) 2020-09-28

Family

ID=66049363

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020009140A MX2020009140A (es) 2018-03-16 2019-03-08 Metodos para el tratamiento de enfermedades oculares.

Country Status (11)

Country Link
US (1) US20210017266A1 (es)
EP (1) EP3765083A1 (es)
JP (3) JP6938796B2 (es)
KR (2) KR20200131839A (es)
CN (1) CN111867631A (es)
AU (2) AU2019235577B2 (es)
CA (1) CA3091096A1 (es)
IL (2) IL277333B2 (es)
MX (1) MX2020009140A (es)
TW (1) TWI727279B (es)
WO (1) WO2019175727A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101482483B1 (ko) 2006-04-07 2015-01-15 에르피오 세러퓨틱스 인코포레이티드 인간 단백질 타이로신 포스파타아제 베타(ｈｐｔｐ베타)에 결합하는 항체 및 그의 용도
ES2687259T5 (es) 2008-06-25 2022-10-14 Novartis Ag Anticuerpos estables y solubles que inhiben TNF
HRP20241467T1 (hr) 2008-06-25 2025-01-03 Novartis Ag Stabilna i topljiva protutijela koja inhibiraju vegf
HUE038432T2 (hu) 2008-06-25 2018-10-29 Esbatech Alcon Biomed Res Unit Nyúl antitestek humanizálása egy univerzális antitest keret alkalmazásával
CA2850830A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
TWI738632B (zh) 2014-11-07 2021-09-11 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
CN108699557B (zh) 2015-12-04 2025-08-15 诺华股份有限公司 用于免疫肿瘤学的组合物和方法
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
KR20190130608A (ko) 2017-03-22 2019-11-22 노파르티스 아게 면역종양학을 위한 조성물 및 방법
US12071476B2 (en) 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
IL277333B2 (en) * 2018-03-16 2026-03-01 Novartis Ag VEGF antagonists for use in the treatment of diabetic macular edema
US10894824B2 (en) 2018-09-24 2021-01-19 Aerpio Pharmaceuticals, Inc. Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF
AU2019407063B2 (en) 2018-12-18 2024-07-04 Novartis Ag Protein solution formulation containing high concentration of an anti-VEGF antibody
MA54325A (fr) 2019-06-05 2022-05-11 Regeneron Pharma Dispositifs et procédés pour l'administration précise de doses
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder
PT3884929T (pt) 2020-03-25 2023-08-09 Ocular Therapeutix Inc Implante ocular contendo um inibidor da tirosina cinase
CN116195003A (zh) * 2020-09-23 2023-05-30 基因泰克公司 对黄斑水肿患者的注射频率的机器学习预测
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
AU2024251447A1 (en) 2023-04-11 2025-08-21 Ocular Therapeutix, Inc. Ocular implant comprising axitinib polymorph iv

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1802334B1 (en) 2004-10-21 2012-08-29 Genentech, Inc. Method for treating intraocular neovascular diseases
HRP20241467T1 (hr) 2008-06-25 2025-01-03 Novartis Ag Stabilna i topljiva protutijela koja inhibiraju vegf
CN103533950A (zh) * 2011-01-13 2014-01-22 瑞泽恩制药公司 Vegf拮抗剂在治疗血管生成眼病中的用途
EP2890389A1 (en) * 2012-08-28 2015-07-08 Novartis AG Use of a vegf antagonist in treating ocular vascular proliferative diseases
TWI738632B (zh) * 2014-11-07 2021-09-11 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
JP6959912B2 (ja) * 2015-09-23 2021-11-05 ジェネンテック， インコーポレイテッド 抗ｖｅｇｆ抗体の最適化変異体
IL277333B2 (en) * 2018-03-16 2026-03-01 Novartis Ag VEGF antagonists for use in the treatment of diabetic macular edema

Also Published As

Publication number Publication date
JP2021509912A (ja) 2021-04-08
JP2024042697A (ja) 2024-03-28
TW201945027A (zh) 2019-12-01
AU2019235577A1 (en) 2020-08-27
AU2019235577B2 (en) 2021-09-30
WO2019175727A1 (en) 2019-09-19
AU2021286278A1 (en) 2022-01-20
TWI727279B (zh) 2021-05-11
CN111867631A (zh) 2020-10-30
KR20200131839A (ko) 2020-11-24
RU2020133816A (ru) 2022-04-18
RU2020133816A3 (es) 2022-04-18
AU2021286278B2 (en) 2023-09-14
IL277333B1 (en) 2025-11-01
KR20260036043A (ko) 2026-03-13
IL323849A (en) 2025-12-01
IL277333A (en) 2020-10-29
JP2021191778A (ja) 2021-12-16
EP3765083A1 (en) 2021-01-20
IL277333B2 (en) 2026-03-01
US20210017266A1 (en) 2021-01-21
JP6938796B2 (ja) 2021-09-22
CA3091096A1 (en) 2019-09-19
AU2021286278C1 (en) 2024-05-23

Similar Documents

Publication Publication Date Title
CL2017001117A1 (es) Métodos para tratar enfermedades oculares.
CL2020003223A1 (es) Anticuerpos il-11
MX2021008053A (es) Metodos para monitorear y terapias para usarse en tratar el cancer.
EA201790398A1 (ru) Способы лечения заболевания печени
CO2020004831A2 (es) Dosis y administración de anticuerpos antic-c5 para el tratamiento de pacientes con glomerulonefritis membranoproliferativa
MX2019001581A (es) Inhibidores de ssao de aminopirimidina.
JOP20210166A1 (ar) علاج الصداع الناتج عن فرط استعمال الأدوية باستخدام أجسام مضادة لـcgrp أو أجسام مضادة لـcgrp-r
EA201692436A1 (ru) Медицинское применение
CR20200334A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
MX2020007527A (es) Tratamiento de enfermedades oftalmologicas.
DOP2017000071A (es) Terapia de combinación para alzheimer que usa anticuerpos anti-n3pglu a beta mas un inhibidor de bace.
GT201200318A (es) Anticuerpos hacia gdf8 humano
IL282827A (en) Bispecific cd123 x cd3 diabodies for the treatment of hematologic malignancies
PE20190338A1 (es) Metodos de tratamiento de trastornos del desarrollo con gaboxadol
MA45780B1 (fr) Niraparib pour son utilisation dans une méthode de traitement du cancer de la prostate
SI3773558T1 (sl) Kombinirano zdravljenje artritične bolezni
CO2019004561A2 (es) Métodos de tratamiento de una lesión renal aguda
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
MA40607B1 (fr) Traitements médicaux à base d'anamoréline
MX2022003101A (es) Metodos de tratamiento de enfermedades oculares.
MA53180A (fr) Méthode de génération d'un descendance stérile
IL287832A (en) Methods of administering anti-cd38 antibody to treat multiple myeloma
EA201792610A1 (ru) Способ лечения неврологического заболевания
MX2022012906A (es) Terapia con cer-001 para tratar enfermedad renal.
CL2021001363A1 (es) Métodos de tratamiento de enfermedades con inhibidores de magl.